TQ Therapeutics
Key Facts
| Invested since | 2024 |
| Based in | Planegg |
About the company
TQ Therapeutics GmbH (Martinsried, Germany) is a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies. The company’s mission is to develop a transformative cell processing platform, enabling advanced and affordable treatments in CGT. This technology will deliver highly individualized cell therapies directly to the patent’s bed-side.
Do you want to
know more about this company?
Zum Artikel
Dr. Christian Kannemeier Senior Investment Manager
Dr. Christian KannemeierSenior Investment Manager
TQ Therapeutics in the news
More startups from Life Sciences
Exit
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs. Exit since …
to Corimmun
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
to Tacalyx
CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.
to CorTec
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
to Cryotherapeutics
Optimization of atrial fibrillation therapy via precise, non-thermal pulsed field ablation
to Argá Medtech
Exit
650 million people suffer from mental illness like depression, anxiety or burnout worldwide. Even in developed countries there is a huge treatment gap: 50% do not get treated. Selfapy offers …
to Selfapy
Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting …
to Lymphatica
Dimericon is a private biotech company focused on exploring the novel modality crosslinked helix dimers (Dimericons) to target hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The …
to Dimericon
Exit
multiBIND develops innovative solutions for molecular biology, healthcare and agriculture. bioDECONT® and bioCLEAN represent biocompatible disinfection and decontamination in laboratories, hospitals and agriculture.
to multiBIND
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – …
to Umlaut.bio
WISE Srl is a Milan and Berlin-based company developing genuinely novel and minimally-invasive implantable leads for Neuromodulation and Neuromonitoring: highly conformable, stretchable, unbreakable and cheaper to produce.
to WISE
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
to Resolve Biosciences